Aerpio Therapeutics raises $27 million for novel diabetic macular edema drug
This article was originally published in Scrip
Executive Summary
Aerpio Therapeutics, the Cincinnati, Ohio-based company, raised $27 million in a Series A financing round to fund its first-in-class Tie2 receptor activator AKB-9778 through 2014 when the company plans to complete a Phase II clinical trial in the treatment of diabetic macular edema (DME).